|
ИСТИНА |
Войти в систему Регистрация |
ИСТИНА ЦЭМИ РАН |
||
SARS-CoV-2 Subunit Virus-like Vaccine Demonstrates High Safety Profile and Protective Efficacy: Preclinical Studyстатья
Статья опубликована в высокорейтинговом журнале
Статья опубликована в журнале из списка Web of Science и/или Scopus- Авторы: Vakhrusheva Anna V., Kudriavtsev Aleksandr V., Kryuchkov Nickolay A., Deev Roman V., Frolova Maria E., Blagodatskikh Konstantin A., Djonovic Milana, Nedorubov Andrey A., Odintsova Elena, Ivanov Aleksandr V., Romanovskaya-Romanko Ekaterina A., Stukova Marina A., Isaev Artur A., Krasilnikov Igor V.
- Журнал: VACCINES
- Том: 10
- Номер: 8
- Год издания: 2022
- Первая страница: 1290
- DOI: 10.3390/vaccines10081290
- Аннотация: Public health threat coming from a rapidly developing COVID-19 pandemic calls for developing safe and effective vaccines with innovative designs. This paper presents preclinical trial results of “Betuvax-CoV-2”, a vaccine developed as a subunit vaccine containing a recombinant RBD-Fc fusion protein and betulin-based spherical virus-like nanoparticles as an adjuvant (“Betuspheres”). The study aimed to demonstrate vaccine safety in mice, rats, and Chinchilla rabbits through acute, subchronic, and reproductive toxicity studies. Along with safety, the vaccine demonstrated protective efficacy through SARS-CoV-2-neutralizing antibody production in mice, rats, hamsters, rabbits, and primates (rhesus macaque), and lung damage and infection protection in hamsters and rhesus macaque model. Eventually, “Betuvax-CoV-2” was proved to confer superior efficacy and protection against the SARS-CoV-2 in preclinical studies. Based on the above results, the vaccine was enabled to enter clinical trials that are currently underway.
- Добавил в систему: Вахрушева Анна Владимировна